Indegene Ltd (INDGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Indegene Ltd (INDGN) has a cash flow conversion efficiency ratio of 0.071x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs2.03 Billion ≈ $21.93 Million USD) by net assets (Rs28.66 Billion ≈ $309.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See INDGN days of operational coverage to measure how many days the company can operate on defensive assets alone.
Indegene Ltd - Cash Flow Conversion Efficiency Trend (2020–2026)
This chart illustrates how Indegene Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Indegene Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indegene Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Companhia Siderúrgica Nacional
SA:CSNA3
|
0.023x |
|
Cardinal Energy Ltd
TO:CJ
|
0.049x |
|
Jinlongyu Group Co Ltd Class A
SHE:002882
|
0.066x |
|
Techno Electric & Engineering Company Limited
NSE:TECHNOE
|
-0.045x |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
0.016x |
|
Zhongli Science and Technology Group Co Ltd
SHE:002309
|
0.182x |
|
Odontoprev S.A
SA:ODPV3
|
0.005x |
|
CONSUN PHARMAC.GR.HD -10
F:C1P
|
N/A |
Annual Cash Flow Conversion Efficiency for Indegene Ltd (2020–2026)
The table below shows the annual cash flow conversion efficiency of Indegene Ltd from 2020 to 2026. For the full company profile with market capitalisation and key ratios, see market cap of Indegene Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs31.39 Billion ≈ $339.44 Million |
Rs6.63 Billion ≈ $71.74 Million |
0.211x | +25.10% |
| 2025-03-31 | Rs26.16 Billion ≈ $282.87 Million |
Rs4.42 Billion ≈ $47.79 Million |
0.169x | -52.44% |
| 2024-03-31 | Rs14.29 Billion ≈ $154.55 Million |
Rs5.08 Billion ≈ $54.91 Million |
0.355x | +190.20% |
| 2023-03-31 | Rs10.64 Billion ≈ $115.04 Million |
Rs1.30 Billion ≈ $14.08 Million |
0.122x | -68.52% |
| 2022-03-31 | Rs7.64 Billion ≈ $82.61 Million |
Rs2.97 Billion ≈ $32.12 Million |
0.389x | -24.71% |
| 2021-03-31 | Rs3.33 Billion ≈ $36.02 Million |
Rs1.72 Billion ≈ $18.60 Million |
0.516x | +136.17% |
| 2020-03-31 | Rs-155.98 Million ≈ $-1.69 Million |
Rs222.73 Million ≈ $2.41 Million |
-1.428x | -- |
About Indegene Ltd
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It al… Read more